Practical guidelines for effective treatment of the osteodystrophic uraemic syndrome with intravenous calcitriol

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 3, 1996, Pages 50-53

  Cannella, G ^a   Moriero, E ^a   Rolla, D ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; TREATMENT FAILURE; UREMIA;

EID: 0029736642     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp3.50     Document Type: Conference Paper

References (27)

1. Slatopolsky E, Delmez J. Bone disease in chronic renal failure and after transplantation. In: Coe FI, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. New York, Raven Press, 1992: 905-934
2. Mak RHK. Early history of renal rickets. Am J Nephrol 1993; 13: 293-297
3. Silver J. Regulation of parathyroid hormone synthesis and secretion. In: Coe FL, Favus MJ, ed, Disorders of Bone and Mineral Metabolism. New York, Raven Press, 1992: 83-106
4. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin JK. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
5. Salusky IB, Goodman WG, Horst R et al. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 1990; XVI(2): 126-132
6. Cannella G, Bonucci E, Rolla D et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-1132
7. Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992; 42: 1191-1198
8. Gallieni M, Brancaccio D. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 1994; 9: 1816-1821
9. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-1098
10. Malberti F, Surian M, Cosci P. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7: 822-828
11. Portale AA, Both BE, Halloran BP, Morris RC. Effects of dietary phosphorus on circulating concentrations of 1.25 dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73: 1580-1589
12. Silver J. What stimuli control the activity of the parathyroid cell? Nephrol Dial Transplant 1995; 10: 599-600
13. 3 and ionized calcium in renal failure (abstract). J Am Soc Nephrol 1994; 5: 889
14. Quarles LD, Yohai DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 44: 1259-1265
15. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991; 2: 1014-1020
16. Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994; 67: 48-53
17. 3 pulse therapy' on hemodialysis patients with secondary hyperparathyroidism. Nephron 1991; 57: 23-28
18. 3. Nephron 1991; 58: 288-94
19. 3 and dyalisate with 3 mEq/L calcium concentration. Am J of Nephrol 1993; 13: 149-154
20. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993; 40(4): 216-220
21. Mazzaferro S, Pasquali M, Ballanti P et al. Intravenous versus oral calcitriol therapy in renal osteodistrophy: results of a prospective, pulsed and dose-comparable study. Min Electrolyte Metab 1994; 20: 122-129
22. Cohen Solal ME, Sebert JL, Boudaillez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrin Metab 1991; 73: 516-524
23. Quarles DL, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrin Metab 1992; 75: 145-150
24. Torres A, Lorenzo V, Hernàndez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442
25. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
26. Dressler R, Laut J, Lynn RI, Ginsberg N. Long-term high dose intravenous calcitriol therapy in end stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 1995; 43(5): 324-331
27. Slatopolsky E, Weerts C, Norwood K et al. Long-term effect of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36: 897-903